Treatment of mycobacterium abscessus infection

Shannon A. Novosad, Susan E. Beekmann, Philip M. Polgreen, Kate Mackey, Kevin Winthrop

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Mycobacterium abscessus is often resistant to multiple antimicrobial drugs, and data supporting effective drugs or dosing regimens are limited. To better identify treatment approaches and associated toxicities, we collected a series of case reports from the Emerging Infections Network. Side effects were common and often led to changing or discontinuing therapy.

Original languageEnglish (US)
Pages (from-to)511-514
Number of pages4
JournalEmerging Infectious Diseases
Volume22
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Mycobacterium Infections
Mycobacterium
Pharmaceutical Preparations
Infection
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Epidemiology

Cite this

Novosad, S. A., Beekmann, S. E., Polgreen, P. M., Mackey, K., & Winthrop, K. (2016). Treatment of mycobacterium abscessus infection. Emerging Infectious Diseases, 22(3), 511-514. https://doi.org/10.3201/eid2203.150828

Treatment of mycobacterium abscessus infection. / Novosad, Shannon A.; Beekmann, Susan E.; Polgreen, Philip M.; Mackey, Kate; Winthrop, Kevin.

In: Emerging Infectious Diseases, Vol. 22, No. 3, 01.03.2016, p. 511-514.

Research output: Contribution to journalArticle

Novosad, SA, Beekmann, SE, Polgreen, PM, Mackey, K & Winthrop, K 2016, 'Treatment of mycobacterium abscessus infection', Emerging Infectious Diseases, vol. 22, no. 3, pp. 511-514. https://doi.org/10.3201/eid2203.150828
Novosad, Shannon A. ; Beekmann, Susan E. ; Polgreen, Philip M. ; Mackey, Kate ; Winthrop, Kevin. / Treatment of mycobacterium abscessus infection. In: Emerging Infectious Diseases. 2016 ; Vol. 22, No. 3. pp. 511-514.
@article{f215235568024fb79c0654452d2031ff,
title = "Treatment of mycobacterium abscessus infection",
abstract = "Mycobacterium abscessus is often resistant to multiple antimicrobial drugs, and data supporting effective drugs or dosing regimens are limited. To better identify treatment approaches and associated toxicities, we collected a series of case reports from the Emerging Infections Network. Side effects were common and often led to changing or discontinuing therapy.",
author = "Novosad, {Shannon A.} and Beekmann, {Susan E.} and Polgreen, {Philip M.} and Kate Mackey and Kevin Winthrop",
year = "2016",
month = "3",
day = "1",
doi = "10.3201/eid2203.150828",
language = "English (US)",
volume = "22",
pages = "511--514",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "3",

}

TY - JOUR

T1 - Treatment of mycobacterium abscessus infection

AU - Novosad, Shannon A.

AU - Beekmann, Susan E.

AU - Polgreen, Philip M.

AU - Mackey, Kate

AU - Winthrop, Kevin

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Mycobacterium abscessus is often resistant to multiple antimicrobial drugs, and data supporting effective drugs or dosing regimens are limited. To better identify treatment approaches and associated toxicities, we collected a series of case reports from the Emerging Infections Network. Side effects were common and often led to changing or discontinuing therapy.

AB - Mycobacterium abscessus is often resistant to multiple antimicrobial drugs, and data supporting effective drugs or dosing regimens are limited. To better identify treatment approaches and associated toxicities, we collected a series of case reports from the Emerging Infections Network. Side effects were common and often led to changing or discontinuing therapy.

UR - http://www.scopus.com/inward/record.url?scp=84958760756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958760756&partnerID=8YFLogxK

U2 - 10.3201/eid2203.150828

DO - 10.3201/eid2203.150828

M3 - Article

C2 - 26890211

AN - SCOPUS:84958760756

VL - 22

SP - 511

EP - 514

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 3

ER -